UBS Group’s Jasper Therapeutics JSPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.31M | Sell |
416,275
-118,361
| -22% | -$657K | ﹤0.01% | 3703 |
|
|
2025
Q1 | $2.3M | Buy |
534,636
+370,321
| +225% | +$1.59M | ﹤0.01% | 3608 |
|
|
2024
Q4 | $3.51M | Buy |
164,315
+158,998
| +2,990% | +$3.4M | ﹤0.01% | 3273 |
|
|
2024
Q3 | $100K | Buy |
5,317
+1,265
| +31% | +$23.8K | ﹤0.01% | 5182 |
|
|
2024
Q2 | $92K | Buy |
+4,052
| New | +$92K | ﹤0.01% | 5098 |
|
|
2023
Q1 | – | Sell |
-21,552
| Closed | -$103K | – | 8739 |
|
|
2022
Q4 | $103K | Buy |
21,552
+2,749
| +15% | +$13.2K | ﹤0.01% | 4947 |
|
|
2022
Q3 | $148K | Buy |
18,803
+18,249
| +3,294% | +$144K | ﹤0.01% | 4329 |
|
|
2022
Q2 | $11K | Buy |
+554
| New | +$11K | ﹤0.01% | 6779 |
|
|
2022
Q1 | – | Sell |
-255
| Closed | -$20K | – | 9384 |
|
|
2021
Q4 | $20K | Buy |
255
+201
| +372% | +$15.8K | ﹤0.01% | 6723 |
|
|
2021
Q3 | $6K | Sell |
54
-123
| -69% | -$13.7K | ﹤0.01% | 7277 |
|
|
2021
Q2 | $18K | Buy |
177
+44
| +33% | +$4.48K | ﹤0.01% | 6354 |
|
|
2021
Q1 | $13K | Sell |
133
-352
| -73% | -$34.4K | ﹤0.01% | 6712 |
|
|
2020
Q4 | $49K | Buy |
485
+419
| +635% | +$42.3K | ﹤0.01% | 5204 |
|
|
2020
Q3 | $7K | Sell |
66
-114
| -63% | -$12.1K | ﹤0.01% | 6236 |
|
|
2020
Q2 | $18K | Buy |
180
+40
| +29% | +$4K | ﹤0.01% | 5773 |
|
|
2020
Q1 | $13K | Buy |
+140
| New | +$13K | ﹤0.01% | 5865 |
|